

## PRIOR AUTHORIZATION POLICY

**POLICY:** Inflammatory Conditions – Taltz® (ixekizumab for subcutaneous injection – Eli Lilly and Company)

**DATE REVIEWED:** 04/08/2020

---

### OVERVIEW

Taltz is a humanized immunoglobulin G (IgG) subclass 4 monoclonal antibody with neutralizing activity against interleukin (IL)-17A.<sup>1</sup> It is indicated for the following uses:

1. Ankylosing spondylitis, in adults with active disease; AND
2. Plaque psoriasis, treatment of patients  $\geq 6$  years of age with moderate to severe disease who are candidates for systemic therapy or phototherapy; AND
3. Psoriatic arthritis, treatment of adults with active disease.

In plaque psoriasis, the recommended dose is 160 mg (administered as two 80-mg subcutaneous [SC] injections) at Week 0 followed by 80 mg SC at Weeks 2, 4, 6, 8, and 12, then 80 mg every 4 weeks (Q4W) thereafter. In psoriatic arthritis and ankylosing spondylitis, the dose is 160 mg at Week 0, followed by 80 mg Q4W. For patients with psoriatic arthritis, if the patient has coexisting moderate to severe plaque psoriasis the psoriasis dosing should be used. In psoriatic arthritis, Taltz may be given alone or in combination with a conventional synthetic disease-modifying antirheumatic drug (DMARD) [e.g., methotrexate]. Taltz is intended for use under the guidance and supervision of a physician. Those trained in SC injection technique using the pen or prefilled syringe may self-inject when deemed appropriate.

### Disease Overview

Although the etiology of psoriasis is not fully established, abnormal keratin formation, epidermal proliferation, activation of the immune system, and hereditary factors appear to play roles in the pathogenesis of the disease. Psoriatic plaques show infiltrates of activated T cells which produce pro-inflammatory cytokines, including IL-17 and tumor necrosis factor (TNF)- $\alpha$ . By blocking the release of proinflammatory cytokines and chemokines, Taltz has an inhibitory effect on the inflammatory process.

### Guidelines

- Ankylosing Spondylitis: Guidelines for ankylosing spondylitis and nonradiographic axial spondylitis are published by the American College of Rheumatology (ACR)/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network (2019).<sup>2</sup> Following primary nonresponse to a TNFi, either Cosentyx or Taltz is recommended; however, if the patient is a secondary nonresponder, a second TNFi is recommended over switching out of the class. In patients with a contraindication to a TNFi, use of an IL blocker is recommended over traditional oral agents such as methotrexate or sulfasalazine.
- Plaque Psoriasis: Joint guidelines from the American Academy of Dermatology (AAD) and National Psoriasis Medical Board (2019) have been published for management of psoriasis with biologics.<sup>3</sup> These guidelines list Taltz as a monotherapy treatment option for patients with moderate to severe plaque psoriasis. Guidelines from the European Dermatology Forum (EDF) [2015] recommend biologics (i.e., etanercept, adalimumab, infliximab, Stelara SC) as second-line therapy for induction and long-term treatment if phototherapy and conventional systemic agents have failed, are contraindicated, or are not tolerated.<sup>4</sup>

- **Psoriatic Arthritis:** Guidelines from the American College of Rheumatology (ACR) [2019] recommend TNF inhibitors over other biologics for use in treatment-naïve patients with PsA and in those who were previously treated with an oral therapy.<sup>5</sup>

### **POLICY STATEMENT**

Prior authorization is recommended for prescription benefit coverage of Taltz. Because of the specialized skills required for evaluation and diagnosis of patients treated with Taltz as well as the monitoring required for adverse events and long-term efficacy, initial approval requires Taltz to be prescribed by or in consultation with a physician who specializes in the condition being treated. All approvals are for the duration noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days.

**Automation:** None.

### **RECOMMENDED AUTHORIZATION CRITERIA**

Coverage of Taltz is recommended in those who meet the following criteria:

#### **FDA-Approved Indications**

**1. Ankylosing Spondylitis.** Approve for the duration noted if the patient meets ONE of the following (A or B):

**A) Initial Therapy.** Approve for 3 months if prescribed by or in consultation with a rheumatologist.

**B) Patient is Currently Receiving Taltz.** Approve for 3 years if the patient has had a response, as determined by the prescriber.

Note: Examples of a response to therapy include decreased pain or stiffness, improved function or activities of daily living. The patient may not have a full response, but there should have been a recent or past response to Taltz. The patient may not have a full response, but there should have been a recent or past response to Taltz.

**2.—Plaque Psoriasis.** Approve Taltz for the duration noted if the patient meets ONE of the following conditions (A or B):

**A) Initial Therapy.** Approve for 3 months if the patient meets ALL of the following criteria (i, ii, and iii):

**i.** The patient is  $\geq 6$  years of age; AND

**ii.** The patient meets ONE of the following conditions (a or b):

**a)** The patient has tried at least at least one traditional systemic agent for psoriasis for at least 3 months, unless intolerant.

Note: Examples include methotrexate (MTX), cyclosporine, acitretin [Soriatane<sup>®</sup>, generics], or psoralen plus ultraviolet A light (PUVA). An exception to the requirement for a trial of one traditional systemic agent for psoriasis can be made if the patient has already had a 3-month trial or previous intolerance to at least one biologic. Refer to [Appendix](#) for examples of biologics used for plaque psoriasis. These patients who have already tried a biologic for psoriasis are not required to “step back” and try a traditional systemic agent for psoriasis); OR

**b)** The patient has a contraindication to methotrexate (MTX), as determined by the prescribing physician; AND

**iii.** The agent is prescribed by or in consultation with a dermatologist.

**B) Patient is Currently Receiving Taltz.** Approve for 3 years if the patient has responded, as determined by the prescriber.

Note: The patient may not have a full response, but there should have been a recent or past response to Taltz.

**3. Psoriatic Arthritis (PsA).** Approve Taltz for the duration noted if the patient meets ONE of the following conditions (A or B):

**A) Initial Therapy.** Approve for 3 months if prescribed by or in consultation with a rheumatologist or a dermatologist.

**B) Patient is Currently Receiving Taltz.** Approve for 3 years if the patient has responded as determined by the prescriber.

Note: Examples of a response include less joint pain, morning stiffness, or fatigue; improved function or activities of daily living; decreased soft tissue swelling in joints or tendon sheaths; improvements in acute phase reactants [for example, C-reactive protein [CRP]]. The patient may not have a full response, but there should have been a recent or past response to Taltz.

### CONDITIONS NOT RECOMMENDED FOR APPROVAL

Taltz has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. Rationale for non-coverage for these specific conditions is provided below. (Note: This is not an exhaustive list of Conditions Not Recommended for Approval.)

- 1. Concurrent Use with other Biologics or with Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs).** Taltz should not be administered in combination with a biologic used for an inflammatory condition (see [Appendix](#) for examples). Combination therapy with biologics and/or biologics + targeted synthetic DMARDs has a potential for a higher rate of adverse effects and lack controlled trial data in support of additive efficacy.<sup>6,7</sup> Note: This does NOT exclude the use of MTX (a traditional systemic agent used to treat psoriasis) in combination with Taltz.
- 2. Inflammatory Bowel Disease (i.e., Crohn's disease, ulcerative colitis).** Exacerbations of inflammatory bowel disease, in some cases serious, occurred in clinical trials with Taltz-treated patients.<sup>1</sup>
- 3.** Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

### REFERENCES

1. Taltz<sup>®</sup> injection [prescribing information]. Indianapolis, IN: Eli Lilly and Company; August 2019.
2. Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. *Arthritis Rheumatol*. 2019 Aug 22. [Epub ahead of print].
3. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019 Feb 13. [Epub ahead of print].
4. Nast A, Gisondi P, Ormerod AD, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – EDF in cooperation with EADV and IPC. *J Eur Acad Dermatol Venereol*. 2015;29(12):2277-2294.
5. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis. *Arthritis Care Res (Hoboken)*. 2019;71(1):2-29.
6. Furst DE, Keystone EC, So AK, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. *Ann Rheum Dis*. 2013;72 Suppl 2:ii2-34.
7. Otezla<sup>®</sup> tablets [prescribing information]. Summit, NJ: Celgene Corporation; July 2019.

**APPENDIX**

	<b>Mechanism of Action</b>	<b>Examples of Inflammatory Indications for Products*</b>
<b>Biologics</b>		
<b>Adalimumab SC Products</b> (Humira®, biosimilars)	Inhibition of TNF	AS, CD, PJIA, PsO, PsA, RA, SJIA, UC
<b>Cimzia®</b> (certolizumab pegol SC injection)	Inhibition of TNF	AS, CD, PsO, PsA, RA
<b>Etanercept SC Products</b> (Enbrel®, biosimilars)	Inhibition of TNF	AS, PJIA, PsO, PsA, RA, SJIA
<b>Infliximab IV Products</b> (Remicade®, biosimilars)	Inhibition of TNF	AS, CD, PJIA, PsO, PsA, RA, SJIA, UC
<b>Simponi®, Simponi® Aria™</b> (golimumab SC injection, golimumab IV infusion)	Inhibition of TNF	SC formulation: AS, PsA, RA, UC
		IV formulation: AS, PsA, RA
<b>Actemra®</b> (tocilizumab IV infusion, tocilizumab SC injection)	Inhibition of IL-6	SC formulation: PJIA, RA, SJIA
		IV formulation: PJIA, RA, SJIA
<b>Kevzara®</b> (sarilumab SC injection)	Inhibition of IL-6	RA
<b>Orencia®</b> (abatacept IV infusion, abatacept SC injection)	T-cell costimulation modulator	SC formulation: PJIA, PSA, RA
		IV formulation: PJIA, PsA, RA
<b>Rituximab IV Products</b> (Rituxan®, biosimilars)	CD20-directed cytolytic antibody	RA
<b>Ilaris</b> (canakinumab SC injection)	Inhibition of IL-1β	SJIA
<b>Kineret®</b> (anakinra SC injection)	Inhibition of IL-1	RA, SJIA <sup>^</sup>
<b>Stelara®</b> (ustekinumab SC injection, ustekinumab IV infusion)	Inhibition of IL-12/23	SC formulation: CD, PsO, PsA, UC
		IV formulation: CD, UC
<b>Siliq™</b> (brodalumab SC injection)	Inhibition of IL-17	PsO
<b>Cosentyx™</b> (secukinumab SC injection)	Inhibition of IL-17A	AS, PsO, PsA
<b>Taltz®</b> (ixekizumab SC injection)	Inhibition of IL-17A	AS, PsO, PsA
<b>Ilumya™</b> (tildrakizumab-asmn SC injection)	Inhibition of IL-23	PsO
<b>Skyrizi™</b> (risankizumab-rzza SC injection)	Inhibition of IL-23	PsO
<b>Tremfya™</b> (guselkumab SC injection)	Inhibition of IL-23	PsO
<b>Entyvio™</b> (vedolizumab IV infusion)	Integrin receptor antagonist	CD, UC
<b>Targeted Synthetic DMARDs</b>		
<b>Otezla®</b> (apremilast tablets)	Inhibition of PDE4	PsO, PsA
<b>Olumiant®</b> (baricitinib tablets)	Inhibition of the JAK pathways	RA
<b>Rinvoq®</b> (upadacitinib extended-release tablets)	Inhibition of the JAK pathways	RA
<b>Xeljanz®, Xeljanz XR</b> (tofacitinib tablets, tofacitinib extended-release tablets)	Inhibition of the JAK pathways	RA, PsA, UC

\* Not an all-inclusive list of indication (e.g., oncology indications and rare inflammatory conditions are not listed). Refer to the prescribing information for the respective agent for FDA-approved indications; SC – Subcutaneous; TNF – Tumor necrosis factor; IV – Intravenous; IL – Interleukin; PDE4 – Phosphodiesterase 4; JAK – Janus kinase; AS – Ankylosing spondylitis; CD – Crohn’s disease; PJIA – Polyarticular juvenile idiopathic arthritis; PsO – Plaque psoriasis; PsA – Psoriatic arthritis; RA – Rheumatoid arthritis; SJIA – Systemic juvenile idiopathic arthritis; UC – Ulcerative colitis; <sup>^</sup> Off-label use of SJIA supported in guidelines.